Summary

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$5.25 1,600,000 Positive High 527.13%

Offering Team

  • Legal counsel
  • Lowenstein Sandler LLP
  • Auditors
  • Marcum LLP

Deal Highlights

We are an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). Antipurinergic therapies target the excess production of purines in cells, which can offset homeostasis and result in an overproduction of cellular adenosine triphosphate (or ATP), the main energy molecule in all living cells.

O More

Deal Tracker

IPO Dates

Filing 25 Aug, 2022

Offer 26 Aug, 2022

Look Ahead

Lock Up Expiry Feb 26, 2023

IPO Terms

Offer Price $5.25
Offer Size 1M

Market Sentiments

Stock Price